Torre Lazur McCann Readies Push for Mucinex | Adweek Torre Lazur McCann Readies Push for Mucinex | Adweek
Advertisement

Torre Lazur McCann Readies Push for Mucinex

Advertisement

NEW YORK Adams Respiratory Therapeutics is launching its new product Mucinex next month and has awarded the consumer advertising to Interpublic Group's Torre Lazur McCann Healthcare, the client said.

The Chester, N.J., client markets and sells respiratory disease medications. Torre Lazur joined the roster in 2003, handling the company's professional and managed-care business. Ad spending was not disclosed.

In a statement, client president and CEO Michael Valentino said, "The agency's strategic and creative recommendations have demonstrated an astute knowledge of our products and customers. By strengthening our bond with Torre Lazur McCann, we hope to capitalize on the synergy of having all our advertising at one agency, so that we can grow our entire respiratory portfolio."

Torre Lazur U.S. CEO Beverly Breitenbach said she wants clients to think of the agency as being able to handle both consumer and professional-targeted accounts. In a statement, she said, "We plan to serve all of Adams' advertising needs in a holistic fashion [via] integrating communications."

Adams vp of business development and consumer marketing Bob Casale will partner with Torre Lazur's Matt Leung, who will run the account, and the creative team of Vanessa Levin and Jennifer Alampi.

Torre Lazur is a 25-year-old healthcare agency based in Parsippany, N.J. Its other clients include Sanofi, Daiichi, Eisai, Janssen, GlaxoSmithKline, Gilead, Chiron, Ortho-McNeil, Pfizer, Sepracor and Roche Laboratories.